The Onvansertib Opportunity Company Overview Forward-Looking Statements Certain statements in this presentation are FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are based on our current expectations and actu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35558 CARDIFF ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction of ...

The Onvansertib Opportunity Company Overview Forward-Looking Statements Certain statements in this presentation are FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are based on our current expectations and actu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF ONCOLOGY, INC. (Exact Name of registrant as specified in its charter) Delaware 27-2004382 (State or other j ...

Turning the Tide on Cancer September 2021 | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------| | | | | Forward-Looking Statements | | | Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of | 1995. These | Corporate Overview Clinical stage oncology company, developing new precision medicine ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF ONCOLOGY, INC. (Exact Name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisd ...

Drug Efficacy and Clinical Trials - Onvansertib has shown high potency against the PLK1 enzyme with an IC50 of 2 nM, while demonstrating low activity on a panel of 63 kinases (IC50 > 500 nM) [80] - In a Phase 1b/2 trial for KRAS-mutated metastatic colorectal cancer (mCRC), 39% of evaluable patients achieved an objective response, significantly higher than the current standard of care benchmarks of 5% to 13% [89] - The median progression-free survival (mPFS) for patients in the KRAS-mutated mCRC trial is currently 9.4 months, compared to standard benchmarks of 4.5 to 5.7 months [89] - In the ongoing Phase 2 study for metastatic castration-resistant prostate cancer (mCRPC), 63% of patients in the continuous dosing schedule achieved the primary endpoint, with 75% showing stable disease at 12 weeks [94] - The Phase 2 study for metastatic pancreatic ductal adenocarcinoma (PDAC) is set to enroll its first patient in the first half of 2021, combining onvansertib with nanoliposomal irinotecan and 5-FU [99] - Onvansertib has demonstrated synergy with multiple chemotherapies and targeted therapeutics, including irinotecan, 5-FU, and abiraterone, enhancing treatment efficacy across various cancer types [82] - The clinical development programs utilize tumor genomics and biomarker technology to assess patient response to treatment, aiming to improve overall survival [78] - The company has completed a Phase 1 safety study of onvansertib, which reported only mild to moderate side effects, indicating a favorable safety profile [80] - Onvansertib's pharmacokinetics include a 24-hour half-life and oral bioavailability, allowing for flexible dosing and scheduling [83] Financial Performance - The accumulated deficit of the company through March 31, 2021, is $236.7 million, with minimal revenues generated to date [101] - Total revenues for the three months ended March 31, 2021, were $0.1 million, unchanged from the prior period, derived from sales-based royalties unrelated to onvansertib [106] - Research and development expenses increased by $0.6 million to $3.3 million for the three months ended March 31, 2021, primarily due to costs associated with ongoing clinical trials [107] - Selling, general and administrative expenses rose by $0.7 million to $2.2 million for the three months ended March 31, 2021, driven by increased legal fees and stock-based compensation [108] - The net loss attributable to common shareholders for the three months ended March 31, 2021, was $5.2 million, an increase of $1.1 million compared to the same period in 2020 [111] - Net cash used in operating activities for the three months ended March 31, 2021, was $5.9 million, compared to $3.4 million for the same period in 2020 [113] - Net cash used in investing activities was $111.7 million during the three months ended March 31, 2021, primarily related to net purchases of marketable securities [114] - As of March 31, 2021, the company had $125.6 million in cash, cash equivalents, and short-term investments, sufficient to meet funding requirements for at least the next 12 months [115] - The company expects to continue incurring losses and will require additional capital to advance clinical trial programs and support operations [116] - The company has no off-balance sheet arrangements as of March 31, 2021 [103] Intellectual Property - The exclusive license agreement for onvansertib includes 3 issued patents covering its composition, salt forms, and combinations with other drugs [79]

Turning the Tide on Cancer March 2021 | --- | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35558 CARDIFF ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction of ...

Onvansertib: A Promising Cancer Therapy - Onvansertib is a 3rd generation, 1st-in-class, oral PLK1 inhibitor with high selectivity and a 24-hour half-life, targeting a key mechanism of cell division required for tumor cell viability[2,8,11] - Clinical data supports the use of onvansertib in combination regimens across numerous aggressive cancers, including mCRC, mCRPC, and AML[2] - The company has a diversified pipeline across numerous cancers and an integrated biomarker strategy, including circulating tumor DNA and circulating tumor cells, to predict therapeutic response[2,5] mCRC (Metastatic Colorectal Cancer) Program - In a Phase 1b/2 trial in KRAS-mutated mCRC, preliminary clinical data showed a ten-fold improvement in Overall Response Rate (ORR) compared to Standard of Care (SOC)[2] - Current second-line standard-of-care treatment in KRAS-mutated mCRC has an overall response rate of 4% and progression-free survival (PFS) of 5.5 months[17] - In the Phase 1b/2 trial, 10 of 11 (91%) patients had clinical benefit, with 5 (45%) patients achieving a partial response (PR)[42] - Monitoring KRAS mutations in plasma ctDNA may enable rapid predictions of therapeutic response, with the greatest changes in KRAS observed in patients achieving a PR[47] mCRPC (Metastatic Castration-Resistant Prostate Cancer) Program - Resistance develops to treatment with standard of care ARSi's within 9-15 months, and ARSi's offer a median overall survival (mOS) benefit of only ~4 months[52] - Phase 2 data demonstrated that 5 (29%) in Arm A, 3 (33%) in Arm B and 2 (67%) in Arm C achieved disease control at 12 weeks[64] - In the Phase 2 trial, 5 (50%) patients had an ≥80% CTC decrease, and 4 (40%) patients converted from unfavorable to favorable CTC level[68] Corporate Information - As of October 31, 2020, the company had $131.8 million in cash and cash equivalents, with an average quarterly cash burn of $3.8 million for Q1-Q3 2020[88]